Almirall Projects to Reach Revenues of €1 Billion in 2025
The Catalan pharmaceutical company Almirall earned €4.3 million in 2022 and surpassed the losses of €40.9 million it had in 2021. The normalized net result, which includes extraordinary items, meant €33.5 million for the company, compared to €81.4 million the previous year. In the first quarter, Almirall reduced its profit by 62%, to €7.7 million, while it increased its sales by 6%, to €232 million.
Almirall plans its recovery. The Catalan laboratory, which has gone through periods of ups and downs in the last decade, will increase its revenue by 15.8% in 2025, to exceed €1 billion, while raising its profits to one hundred million euros, as published by Bloomberg.
This year, the Catalan pharmaceutical company will increase its turnover by 3.2%, up to €891 million. Compared to 2024, the projected increase is 12.6%, reaching €972 million.
Meanwhile, the benefits will be reduced by 10% this year, up to €21.6 million. However, these will double between 2024 and 2025 to €97.9 million. In the longer term, the quoted medium assures that profits will rise to €132 million.
Almirall’s plan to recover the positive path includes the approval of the experimental drug lebrikizumab in the European market. Likewise, Almirall foresees the possible launch of Klisyri against actinic keratosis in 2024 in the United States and in Europe in 2026, as well as Seysara in China against acne also in 2024 or Efinaconazole, for onychomycosis, in 2023.
If you want to find more details about Almirall and to find the most important business news of the day, download for free our companion app Born2Invest.
Almirall will reduce its profits by 10% this year
To continue increasing income, pharmaceutical trusts everything to research. Two weeks ago, the Catalan pharmaceutical company announced that it was going to invest around €400 million in research and development (R&D) projects over the next three years, with the aim of “focusing on new products with a highly innovative base.” The company’s investment in research and development projects stood at €103.2 million in 2022.
In 2022, the company’s total revenue stood at €866.5 million, representing a growth of 6.7%, while the Ebitda was €198.3 million, 15.8% less than in 2021.
The Catalan pharmaceutical company earned €4.3 million in 2022 and surpassed the losses of €40.9 million it had in 2021. The normalized net result, which includes extraordinary items, meant €33.5 million for the company, compared to €81.4 million the previous year.
In the first quarter, Almirall reduced its profit by 62%, to €7.7 million, while it increased its sales by 6%, to €232 million. The investment in R&D undertaken by the Catalan biopharmaceutical company reached €23.9 million, 13% more, while its net debt stood at €216 million.
(Featured image by JoaquinAranoa via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [Week 22]
This week we're waking the dead as we go back to the metaverse baby. With Apple soon announcing its long-awaited...
Bullish on Bitcoin? – Blackrock CEO Warns of “Debt Ceiling Drama”
Many bitcoin and cryptocurrency investor advocates view BTC as a hedge against inflation and debt concerns, especially as central banks...
Docline Prepares a New Round of 6 Million for 2024
Docline maintains an agreement with Mapfre, with whom it offers digital health programs to the company's policyholders; with the Ballesol retirement...
Cedacri Prices New €275M Bond to Pay €50M Tax and €150M Extra Dividend
As stated in the Report to Cedacri's 2022 Annual Report, and as recalled in the release in which Moody's assigned...
Bierzo Aire Limpio Starts Crowdfunding to Support the Legal Defense of the Environment
The NGO holds an assembly that includes a state-wide meeting against waste incineration, debates on wind and solar macro-projects, and...
Crypto4 days ago
Bitcoin: Ordinals Attract Former Ethereum Developers
Cannabis2 weeks ago
Medical Cannabis Could Be the Future of Brain Cancer Treatment
Biotech1 day ago
Sicit Acquires 51% of Plant Biostimulants from Chile’s Patagonia Biotechnology
Cannabis1 week ago
Where Do Cannabis Users Buy Cannabis From: New Frontier Data Study